SpringWorks Therapeutics ready to launch newly-approved desmoid tumor treatment after three-month delay
SpringWorks Therapeutics won FDA approval for its desmoid tumor treatment Ogsiveo on Monday, following a three-month regulatory hiccup.
Desmoid tumors are rare but locally aggressive tumors that grow with tendril-like filaments and can range from the size of a peach to a football, CEO Saqib Islam told Endpoints News. While they don’t metastasize, they have a high rate of recurrence, even with surgery, or in some cases, amputations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.